Dr. Zheng (Jen) Zeng is an IP specialist in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Since 2018, Jen has focused on patent prosecution in fields such as RNA therapeutics, antibody therapies including ADC, cell therapies, single-cell sequencing, and gene editing. She also provides support in various intellectual property matters, including due diligence and freedom-to-operate analyses.
Jen earned her Ph.D. in Biological Science from the University of California, San Diego. Her doctoral research concentrated on the impacts of neurotrophins on axonal transport and neuronal activity. During her graduate studies, Jen led pro bono consulting teams to assess the scientific and market potential of life sciences innovations for San Diego start-ups.
Jen is fluent in Mandarin and Cantonese, enhancing communication with diverse clients.
Dr. Zheng (Jen) Zeng is an IP specialist in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Since 2018, Jen has focused on patent prosecution in fields such as RNA therapeutics, antibody therapies including ADC, cell therapies, single-cell sequencing, and gene editing. She also provides support in various intellectual property matters, including due diligence and freedom-to-operate analyses.
Jen earned her Ph.D. in Biological Science from the University of California, San Diego. Her doctoral research concentrated on the impacts of neurotrophins on axonal transport and neuronal activity. During her graduate studies, Jen led pro bono consulting teams to assess the scientific and market potential of life sciences innovations for San Diego start-ups.
Jen is fluent in Mandarin and Cantonese, enhancing communication with diverse clients.
- Ph.D., Biological Sciences, University of California, San Diego, 2017
- B.S., Biological Science, Sun Yat-Sen University, 2010
Academic Excellence Award by Ministry of Education
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
- Ph.D., Biological Sciences, University of California, San Diego, 2017
- B.S., Biological Science, Sun Yat-Sen University, 2010
Academic Excellence Award by Ministry of Education
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
Biological Sciences and Biotechnology
- Antibody
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Molecular biology
- Neurobiology
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Drug conjugates
- Drug conjugates based drug discovery
- Gene editing
- Gene therapy
- RNA interference (RNAi)
Genomics and Data Analysis
- Next-generation sequencing
- Single-cell sequencing
Miscellaneous
- Cancer
- Food science
Biological Sciences and Biotechnology
- Antibody
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Molecular biology
- Neurobiology
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Drug conjugates
- Drug conjugates based drug discovery
- Gene editing
- Gene therapy
- RNA interference (RNAi)
Genomics and Data Analysis
- Next-generation sequencing
- Single-cell sequencing
Miscellaneous
- Cancer
- Food science
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
- Privacy Policy
- Terms of Use
- Accessibility